Anandamide increases the differentiation of rat adipocytes and causes PPARλ and cB1 receptor upregulation

Obesity

Volumn 17, Issue 10, 2009, Pages 1830-1838

  Karaliota, Sevasti ^a   Siafaka Kapadai, Athanasia ^a   Gontinou, Chrisanthi ^a   Psarra, Katerina ^b   Mavri Vavayanni, Mary ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

RATTUS;

AMIDASE; AMIDE; ANANDAMIDE; ARACHIDONIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; CANNABINOID 1 RECEPTOR; CARBAMIC ACID DERIVATIVE; CYCLOHEXYL CARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; CYCLOOXYGENASE 2; ENZYME INHIBITOR; FATTY ACID AMIDASE; FATTY-ACID AMIDE HYDROLASE; INDOMETACIN; METHANANDAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL; ARTICLE; BIOSYNTHESIS; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; FLOW CYTOMETRY; GENETICS; MALE; METABOLISM; PHYSIOLOGY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; WISTAR RAT;

ADIPOCYTES; ADIPOSE TISSUE; AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BENZAMIDES; BLOTTING, WESTERN; CARBAMATES; CELL DIFFERENTIATION; CYCLOOXYGENASE 2; ENZYME INHIBITORS; FLOW CYTOMETRY; INDOMETHACIN; MALE; POLYUNSATURATED ALKAMIDES; PPAR GAMMA; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 70349513301     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2009.177     Document Type: Article

References (47)

1. Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev 1998;78:783-809.
2. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor γ and metabolic disease. Annu Rev Biochem 2001;70:341-367.
3. Kliewer SA, Sundseth SS, Jones SA et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA 1997;94:4318-4323.
4. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nature 2008;7:438-455.
5. Di Marzo V, Fontana A, Cadas H et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994;372:686-691.
6. Hermann H, De Petrocellis L, Bisogno T et al. Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell Mol Life Sci 2003;60:607-616.
7. Howlett AC, Breivogel CS, Childers SR et al. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004;47 Suppl 1:345-358.
8. Hillard CJ, Jarrahian A. Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol 2003;140:802-808.
9. Rouzer CA, Marnett LJ. Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids. J Biol Chem 2008;283:8065-8069.
10. Elphick MR, Egertová M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond, B, Biol Sci 2001;356:381-408.
11. Karava V, Zafiriou PM, Fasia L et al. Anandamide metabolism by Tetrahymena pyriformis in vitro. Characterization and identification of a 66 kDa fatty acid amidohydrolase. Biochimie 2005;87:967-974.
12. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8:585-589.
13. Di Marzo V, Goparaju SK, Wang L et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-825.
14. Bensaid M, Gary-Bobo M, Esclangon A et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63:908-914.
15. Matias I, Carta G, Murru E et al. Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochim Biophys Acta 2008;1781:52-60.
16. Gasperi V, Fezza F, Pasquariello N et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 2007;64:219-229.
17. Bouaboula M, Hilairet S, Marchand J et al. Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 2005;517:174-181.
18. Pagano C, Pilon C, Calcagno A et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007;92:4810-4819.
19. Hao S, Avraham Y, Mechoulam R, Berry EM. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 2000;392:147-156.
20. Rodbell M. Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 1964;239:375-380.
21. Karagiannides I, Tchkonia T, Dobson DE et al. Altered expression of C/EBP family members results in decreased adipogenesis with aging. Am J Physiol Regul Integr Comp Physiol 2001;280:R1772-R1780.
22. McNeel RL, Mersmann HJ. Effects of isomers of conjugated linoleic acid on porcine adipocyte growth and differentiation. J Nutr Biochem 2003;14: 266-274.
23. Lee YH, Chen SY, Wiesner RJ, Huang YF. Simple flow cytometric method used to assess lipid accumulation in fat cells. J Lipid Res 2004;45:1162-1167.
24. Stellas D, Karameris A, Patsavoudi E. Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. Clin Cancer Res 2007;13:1831-1838.
25. Piomelli D, Tarzia G, Duranti A et al. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 2006;12:21-38.
26. Bishop-Bailey D, Warner TD. PPARγ ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-γ antagonist. FASEB J 2003;17:1925-1927.
27. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;27:73-100.
28. Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor γ independently of cannabinoid receptors 1 and 2. Mol Pharmacol 2006;70:101-111.
29. Guzmán M, LoVerme J, Fu J et al. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor α (PPAR-α). J Biol Chem 2004;279:27849-27854.
30. LoVerme J, Fu J, Astarita G et al. The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005;67:15-19.
31. Spoto B, Fezza F, Parlongo G et al. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie 2006;88:1889-1897.
32. Matias I, Gonthier M P, Orlando P et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006;91:3171-3180.
33. Nieri P, Greco R, Adinolfi B et al. CB1- and CB2-cannabinoid receptor-independent lipolysis induced by WIN 55,212-2 in male rat adipocytes. Naunyn Schmiedebergs Arch Pharmacol 2003;368:352-359.
34. Cota D, Marsicano G, Tschöp M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-431.
35. Starowicz KM, Cristino L, Matias I et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 2008;16:553-565.
36. Engeli S, Böhnke J, Feldpausch M et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838-2843.
37. Osei-Hyiaman D, DePetrillo M, Pacher P et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115:1298-1305.
38. Klein TW, Newton C, Larsen K et al. The cannabinoid system and immune modulation. J Leukoc Biol 2003;74:486-496.
39. Roche R, Hoareau L, Bes-Houtmann S et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 2006;126:177-187.
40. Rockwell CE, Kaminski NE. A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J Pharmacol Exp Ther 2004;311:683-690.
41. Lengqvist J, Mata De Urquiza A, Bergman AC et al. Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor α ligand-binding domain. Mol Cell Proteomics 2004;3:692-703.
42. Ueda N, Puffenbarger RA, Yamamoto S, Deutsch DG. The fatty acid amide hydrolase (FAAH). Chem Phys Lipids 2000;108:107-121.
43. Clapper JR, Duranti A, Tontini A et al. The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues. Pharmacol Res 2006;54:341-344.
44. Kathuria S, Gaetani S, Fegley D et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003;9:76-81.
45. Kozak KR, Crews BC, Morrow JD et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 2002;277:44877- 44885.
46. Chen P, Hu S, Yao J et al. Induction of cyclooxygenase-2 by anandamide in cerebral microvascular endothelium. Microvasc Res 2005;69:28-35.
47. Fowler CJ, Börjesson M, Tiger G. Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase. Br J Pharmacol 2000;131:498-504.